Teresa Biermann

Teresa Biermann

Auto-generated profile, based on publicly available information

Teresa Biermann

Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Schwabachanlage 6, D-91054 Erlangen, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2012 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
EHErnst Hein
Ernst Hein
MNMagdalena Nowak
Magdalena Nowak
OKOlga Kiess
Olga Kiess
TBTeresa Biermann
Teresa Biermann
KBKristina Bayerlein
Kristina Bayerlein
TKThomas Kraus
Thomas Kraus

1 January 2012 in Progress in Neurobiology
Verified
Journal Article
Open access
BLBernd Lenz
Bernd Lenz
CMChristian P. Müller
Christian P. Müller
CSChristina Stoessel
Christina Stoessel
WSWolfgang Sperling
Wolfgang Sperling
TBTeresa Biermann
Teresa Biermann
JKJohannes Konrhuber
Johannes Konrhuber
There are well-known sex differences in the epidemiology and etiopathology of alcohol dependence. Male gender is a crucial risk factor for the onset of alcohol addiction. A directly modifying role of testosterone in alcohol addiction-related behavior is well established. Sex hormones exert both permanent (organizational) and transient (activational) effects on the human brain. The sensitive period for these effects lasts throughout life. In this article, we present a novel early sex hormone activity model of alcohol addiction. We propose that early exposure to sex hormones triggers structural (organizational) neuroadaptations. These neuroadaptations affect cellular and behavioral responses to adult sex hormones, sensitize the brain's reward system to the reinforcing properties of alcohol and modulate alcohol addictive behavior later in life. This review outlines clinical findings related to the early sex hormone activity model of alcohol addiction (handedness, the second-to-fourth-finger length ratio, and the androgen receptor and aromatase) and includes clinical and preclinical literature regarding the activational effects of sex hormones in alcohol drinking behavior. Furthermore, we discuss the role of the hypothalamic-pituitary-adrenal and -gonadal axes and the opioid system in mediating the relationship between sex hormone activity and alcohol dependence. We conclude that a combination of exposure to sex hormones in utero and during early development contributes to the risk of alcohol addiction later in life. The early sex hormone activity model of alcohol addiction may prove to be a valuable tool in the development of preventive and therapeutic strategies.

12 January 2007 in Critical Care
Verified
Journal Article
Open access
PDF file
URUdo Reulbach
Udo Reulbach
CDCarmen Dütsch
Carmen Dütsch
TBTeresa Biermann
Teresa Biermann
WSWolfgang Sperling
Wolfgang Sperling
NTNorbert Thuerauf
Norbert Thuerauf
SBStefan Bleich
Stefan Bleich
Introduction: Neuroleptic malignant syndrome (NMS) is a rare, but sometimes fatal, adverse reaction to neuroleptics characterized principally by fever and rigor. The aim of this study was to prove the efficacy of different NMS treatment strategies, focusing on the efficacy of dantrolene. Methods: Altogether, 271 case reports were included. These cases were categorized into four treatment groups and compared to each other according to effectiveness of therapy within 24 hours, mortality, complete time of remission in days, effectiveness due to increase of dosage, relapse on the basis of decrease of dosage, and improvement of symptoms. Results: Between the four treatment groups, the complete time of remission was significantly different (analysis of variance, F = 4.02; degrees of freedom = 3; p = 0.008). In a logistic regression with adjustment for age, gender, and severity code, no significant predictor of the treatment for the complete time of remission (dichotomized by median) could be found. However, if the premedication was a monotherapy with neuroleptics, the complete time of remission was significantly shorter with dantrolene monotherapy (t = -2.97; p = 0.004). Conclusion: The treatment of NMS with drugs that are combined with dantrolene is associated with a prolongation of clinical recovery. Furthermore, treatment of NMS with dantrolene as monotherapy seems to be associated with a higher overall mortality. Therefore, dantrolene does not seem to be the evidence-based treatment of choice in cases of NMS but might be useful if premedication consisted of a neuroleptic monotherapy.

1 March 2005 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
SBStefan Bleich
Stefan Bleich
MCMarco Carl
Marco Carl
KBKristina Bayerlein
Kristina Bayerlein
URUdo Reulbach
Udo Reulbach
TBTeresa Biermann
Teresa Biermann
JKJohannes Konrhuber
Johannes Konrhuber

1 May 2005 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
DBDominikus Bönsch
Dominikus Bönsch
VGVerena Greifenberg
Verena Greifenberg
KBKristina Bayerlein
Kristina Bayerlein
TBTeresa Biermann
Teresa Biermann
URUdo Reulbach
Udo Reulbach
SBStefan Bleich
Stefan Bleich

7 February 2008 in Epilepsia
Verified
Journal Article
Open access
PDF file
IKInes C. Kanter
Ines C. Kanter
HHHagen B. Huttner
Hagen B. Huttner
DSDimitre Staykov
Dimitre Staykov
TBTeresa Biermann
Teresa Biermann
TSTobias Struffert
Tobias Struffert
JBJürgen Bardutzky
Jürgen Bardutzky
Summary: Glutamic acid decarboxylase (GAD) is the enzyme which catalyzes the production of gamma aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system (CNS). There is increasing evidence that severe GAD autoimmunity may be associated with refractory epilepsy. Immunomodulation and GABAergic drugs have been suggested as treatment options. We report here for the first time on a patient with sudden onset of refractory status epilepticus in the presence of strong intrathecal anti‐GAD antibody synthesis who was successfully treated with cyclophosphamide, and give an overview of available data on epilepsy associated with GAD autoimmunity.